Free Trial

Entera Bio (ENTX) Competitors

Entera Bio logo
$1.86 -0.05 (-2.62%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.83 -0.03 (-1.67%)
As of 07/25/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ENTX vs. ARCT, GLUE, HUMA, CYRX, INBX, TNXP, FHTX, CADL, AURA, and ABEO

Should you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Arcturus Therapeutics (ARCT), Monte Rosa Therapeutics (GLUE), Humacyte (HUMA), CryoPort (CYRX), Inhibrx Biosciences (INBX), Tonix Pharmaceuticals (TNXP), Foghorn Therapeutics (FHTX), Candel Therapeutics (CADL), Aura Biosciences (AURA), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical products" industry.

Entera Bio vs. Its Competitors

Arcturus Therapeutics (NASDAQ:ARCT) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

Arcturus Therapeutics presently has a consensus target price of $54.00, indicating a potential upside of 261.45%. Entera Bio has a consensus target price of $10.00, indicating a potential upside of 437.63%. Given Entera Bio's higher possible upside, analysts plainly believe Entera Bio is more favorable than Arcturus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcturus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
Entera Bio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Entera Bio has lower revenue, but higher earnings than Arcturus Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$152.31M2.66-$80.94M-$2.53-5.91
Entera Bio$180K469.65-$9.54M-$0.26-7.15

Arcturus Therapeutics has a net margin of -47.47% compared to Entera Bio's net margin of -4,525.11%. Arcturus Therapeutics' return on equity of -27.41% beat Entera Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Arcturus Therapeutics-47.47% -27.41% -19.01%
Entera Bio -4,525.11%-95.10%-82.77%

Arcturus Therapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 16.6% of Arcturus Therapeutics shares are held by insiders. Comparatively, 10.4% of Entera Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Entera Bio. MarketBeat recorded 2 mentions for Arcturus Therapeutics and 1 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.87 beat Arcturus Therapeutics' score of 0.94 indicating that Entera Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Arcturus Therapeutics Positive
Entera Bio Very Positive

Summary

Arcturus Therapeutics beats Entera Bio on 12 of the 17 factors compared between the two stocks.

Get Entera Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENTX vs. The Competition

MetricEntera BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$86.81M$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.60%4.01%
P/E Ratio-7.1521.1828.1020.05
Price / Sales469.65286.99429.3789.38
Price / CashN/A42.7636.2258.56
Price / Book8.098.378.665.87
Net Income-$9.54M-$55.19M$3.25B$258.55M
7 Day Performance-9.27%5.88%4.22%3.73%
1 Month Performance-6.77%17.33%10.51%11.75%
1 Year Performance10.06%4.42%34.40%18.03%

Entera Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENTX
Entera Bio
2.9185 of 5 stars
$1.86
-2.6%
$10.00
+437.6%
+6.9%$86.81M$180K-7.1520Positive News
ARCT
Arcturus Therapeutics
2.1609 of 5 stars
$13.79
+2.1%
$54.00
+291.6%
-35.0%$366.13M$152.31M-5.45180
GLUE
Monte Rosa Therapeutics
2.0218 of 5 stars
$5.83
-1.9%
$15.33
+163.0%
+21.4%$365.37M$75.62M72.8890Gap Up
HUMA
Humacyte
1.6488 of 5 stars
$2.30
-1.3%
$11.71
+409.3%
-69.0%$361.43M$1.57M-3.33150News Coverage
Analyst Forecast
CYRX
CryoPort
1.781 of 5 stars
$6.71
-6.7%
$10.88
+62.1%
-12.4%$360.49M$228.38M-2.871,186Analyst Forecast
Insider Trade
INBX
Inhibrx Biosciences
3.1615 of 5 stars
$22.12
-9.5%
N/A+71.9%$353.94M$200K0.19166Positive News
TNXP
Tonix Pharmaceuticals
2.6031 of 5 stars
$45.10
-3.9%
$585.00
+1,197.1%
-14.2%$345.13M$10.09M0.0050
FHTX
Foghorn Therapeutics
2.142 of 5 stars
$6.10
-0.5%
$12.13
+98.8%
-5.1%$341.70M$22.60M-4.49120News Coverage
CADL
Candel Therapeutics
2.0909 of 5 stars
$6.57
-2.5%
$22.00
+234.9%
+7.8%$337.69M$120K-4.9060
AURA
Aura Biosciences
2.4353 of 5 stars
$6.77
+0.9%
$22.00
+225.0%
-29.6%$337.30MN/A-3.5650News Coverage
Positive News
ABEO
Abeona Therapeutics
3.7543 of 5 stars
$6.75
+2.4%
$19.25
+185.2%
+29.8%$337.12M$3.50M-5.3190

Related Companies and Tools


This page (NASDAQ:ENTX) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners